Skip to main content
Premium Trial:

Request an Annual Quote

People in the News at Hologic, Ionpath, Octave Bioscience, Camena Bioscience, Ribbon Biolabs, More

Hologic: Essex Mitchell, Brandon Schnittker

Hologic has appointed Essex Mitchell as the firm's chief operating officer, effective Jan. 1, 2024. He has been the president of Hologic's Gyn Surgical Solutions division since August 2020. Prior to that, he was the division's VP of sales and commercial excellence. Before that, he worked in various commercial roles for medical technology firm Stryker. Brandon Schnittker, VP of surgical sales, will take over as president of the Gyn Surgical Solutions division effective Jan. 1.

Ionpath: Paul Davy, David Summa

Ionpath said today it has appointed Paul Davy as CEO and named outgoing CEO David Summa executive chairman of its board of directors. Davy joined Ionpath in 2021 after prior stints at companies including Molecular Devices and Pall. Summa took over as CEO at Ionpath in May 2023. He is a venture partner at Genoa Ventures. He has 12 years of prior CEO experience at four startups, and was a partner at McKinsey & Company.

Octave Bioscience: Doug Biehn

Octave Biosciences has named Doug Biehn president and CEO. Former CEO William Hagstrom is now chairman of the company's board of directors. Biehn previously held executive positions at companies including iRhythm Technologies, McKesson, AliveCor, Blue Shield of California, and Cala Health.

Camena Bioscience: Nicola Thompson

UK synthetic biology firm Camena Bioscience has appointed Nicola Thompson as chair of its board of directors. Previously, she was the founding CEO of Amphista Therapeutics, and before that, chair of the board of Nanna Therapeutics. She also held senior leadership roles at Roche. Thompson has a PhD in cell biology from University College London.

Ribbon Biolabs: Jodi Barrientos, Harold de Vladar

Austrian DNA synthesis company Ribbon Biolabs has promoted Jodi Barrientos to interim CEO. Earlier this year, she had joined the company as chief business officer. Barrientos succeeds founder Harold de Vladar as CEO, who will remain a member of the company's board and a senior advisor. Prior to joining Ribbon Biolabs, she was VP of commercial marketing for the diagnostics genomics group at Agilent Technologies. She also held leadership roles in commercial operations and sales at Agilent. Before that, she had positions in global product management at Qiagen and in field and technical applications at Roche Diagnostics. She holds a BS in molecular biology and microbiology from Purdue University.

Genetic Signatures: Stephane Chatonsky

Australian molecular diagnostics firm Genetic Signatures has appointed Stephane Chatonsky as a non-executive director. Chatonsky Chatonsky has held senior executive roles with global organizations including Lazard, McKinsey & Co, Macquarie Bank, and LeapFrog Investments. He has also held non-executive director, chair, and advisory positions for several pathology, healthcare, and technology companies.

For additional recent items on executive appointments, promotions, and departures in the omics and molecular diagnostics space, please see the People in the News page on our website.